rs774824237
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 1P and 1B. PP3BS1_Supporting
The NM_007255.3(B4GALT7):c.49A>G(p.Arg17Gly) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000391 in 1,356,524 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. R17R) has been classified as Likely benign.
Frequency
Consequence
NM_007255.3 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- Ehlers-Danlos syndrome, spondylodysplastic type, 1Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), PanelApp Australia, G2P, Ambry Genetics
- Ehlers-Danlos syndrome, spondylodysplastic typeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152026Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.000250 AC: 11AN: 43964 AF XY: 0.000337 show subpopulations
GnomAD4 exome AF: 0.0000399 AC: 48AN: 1204384Hom.: 0 Cov.: 30 AF XY: 0.0000477 AC XY: 28AN XY: 587072 show subpopulations
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152140Hom.: 0 Cov.: 31 AF XY: 0.0000672 AC XY: 5AN XY: 74374 show subpopulations
ClinVar
Submissions by phenotype
Ehlers-Danlos syndrome progeroid type Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with B4GALT7-related conditions. This variant is present in population databases (rs774824237, gnomAD 0.1%). This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 17 of the B4GALT7 protein (p.Arg17Gly). -
Inborn genetic diseases Uncertain:1
The c.49A>G (p.R17G) alteration is located in exon 1 (coding exon 1) of the B4GALT7 gene. This alteration results from a A to G substitution at nucleotide position 49, causing the arginine (R) at amino acid position 17 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at